Skip to Content

Investor Relations

BioScrip®, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S...
Read More

Corporate Profile

BioScrip®, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Investor Overview

News Releases

Date Title and Summary
Toggle Summary BioScrip to Present at Bank of America Merrill Lynch 2017 Leveraged Finance Conference
DENVER , Nov. 16, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Daniel E. Greenleaf , President and Chief Executive Officer, and Stephen Deitsch ,
Toggle Summary BioScrip to Host Meetings at the 8th Annual Craig-Hallum Alpha Select Conference
DENVER , Nov. 09, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that Stephen Deitsch , Senior Vice President, Chief Financial Officer and Treasurer and
Toggle Summary BioScrip Reports Third Quarter 2017 Financial Results
– Net revenue of $198.7 million , including core product mix of 75.0%, compared to 65.8% in the prior year – Net revenue and adjusted EBITDA reduced $10.0 million and $3.0 million , respectively, due to sales disruption from Hurricane Irma, Hurricane Harvey, and completion of the UnitedHealthcare